Probi appoints Jörn Andreas as new CFO

This information was submitted for disclosure on 14 February 2017 at 08.00 (cet).

Probi AB (publ) has appointed Jörn Andreas as CFO. Andreas will replace Niklas Brandt who will remain in Probis leadership team as CIO with responsibility for IT infrastructure and Investor relations.

Jörn Andreas comes from a role as CFO for the Pinova group within Symrise. He has also worked as CFO for the Diana Group, as Director of Corporate development and M&A at Symrise as well as a consultant of the Boston consulting group.  He has also served as a director on Probis board since 2014.

“Jörn Andreas has a proven international track record as CFO and in complex M&A projects, his skills and experience is a perfect match for the next stage of development at Probi which is combining strong organic growth with acquisition growth. Jörn also knows the company very well from his time on the board which will give him a flying start.” says Peter Nählstedt, CEO of Probi. “I would like to thank Niklas Brandt for his excellent work and many years of service as Probi CFO and I am confident he and Jörn Andreas will be very successful in their new roles at Probi.”

“Probi has made tremendous progress in developing into a global leading probiotics group. I very much look forward to my new role at Probi and to further building our growth platform driven by world-class innovation, strong financials and a passionate team,” says Jörn Andreas.

Jörn Andreas will assume his new position on March 1st2017 and will as a result resign from Probis board of Directors.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: peter.nahlstedt@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2016, Probi generated sales of MSEK 444. Probi’s shares are listed on Nasdaq Stockholm, Mid Cap. Probi has about 4,700 shareholders. For more information, please visit www.probi.se.

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 30 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Small-cap. Read more on www.probi.se.

Subscribe

Documents & Links